Evaluates tiomolibdate choline versus standard-of-care in Wilson disease patients, showing improved neurologic outcomes.
To evaluate the neurologic and clinical outcomes of tiomolibdate choline (TMC) compared with standard-of-care (SoC) in Wilson disease (WD) patients with neurologic symptoms.
No takes yet. Share an insight, caveat, or question.
Poujois et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: